These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 15571211

  • 1. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
    Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, MacDonald P, Joseph-Ridge N.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
    Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L.
    Clin Pharmacokinet; 2006 Oct; 45(8):821-41. PubMed ID: 16884320
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
    Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L.
    J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
    Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, Nakachi T, Yamanaka H, Kamatani N.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1119-22. PubMed ID: 15571213
    [Abstract] [Full Text] [Related]

  • 6. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [Abstract] [Full Text] [Related]

  • 7. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME, Fravel MA.
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [Abstract] [Full Text] [Related]

  • 8. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
    Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, Hosoya T.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1117-8. PubMed ID: 15571212
    [Abstract] [Full Text] [Related]

  • 9. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
    Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA.
    Life Sci; 2005 Mar 04; 76(16):1835-47. PubMed ID: 15698861
    [Abstract] [Full Text] [Related]

  • 10. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 04; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [Abstract] [Full Text] [Related]

  • 11. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
    Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L.
    J Clin Pharmacol; 2006 Jan 04; 46(1):88-102. PubMed ID: 16397288
    [Abstract] [Full Text] [Related]

  • 12. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.
    N Engl J Med; 2005 Dec 08; 353(23):2450-61. PubMed ID: 16339094
    [Abstract] [Full Text] [Related]

  • 13. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 08; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [Abstract] [Full Text] [Related]

  • 14. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L.
    J Rheumatol; 2011 Jul 08; 38(7):1385-9. PubMed ID: 21572152
    [Abstract] [Full Text] [Related]

  • 15. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
    Takai M, Yamauchi T, Ookura M, Matsuda Y, Tai K, Kishi S, Yoshida A, Iwasaki H, Nakamura T, Ueda T.
    Anticancer Res; 2014 Dec 08; 34(12):7287-96. PubMed ID: 25503162
    [Abstract] [Full Text] [Related]

  • 16. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
    Horiuchi H, Ota M, Kobayashi M, Kaneko H, Kasahara Y, Nishimura S, Kondo S, Komoriya K.
    Res Commun Mol Pathol Pharmacol; 1999 Dec 08; 104(3):307-19. PubMed ID: 10741381
    [Abstract] [Full Text] [Related]

  • 17. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 08; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [Abstract] [Full Text] [Related]

  • 18. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
    Hosoya T, Ohno I.
    J Clin Rheumatol; 2011 Jun 08; 17(4 Suppl 2):S27-34. PubMed ID: 21654267
    [Abstract] [Full Text] [Related]

  • 19. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 08; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [Abstract] [Full Text] [Related]

  • 20. Febuxostat (Teijin/Ipsen/TAP).
    Tomlinson B.
    Curr Opin Investig Drugs; 2005 Nov 08; 6(11):1168-78. PubMed ID: 16312139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.